APA (7th ed.) Citation

Råket, H. K., Ankarfeldt, M. Z., Wang, J. N., Pressler, T., Jensen-Fangel, S., Qvist, T., . . . Larsen, K. S. B. (2025). Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting. Pulmonary Therapy, 11(2), 235. https://doi.org/10.1007/s41030-025-00287-1

Chicago Style (17th ed.) Citation

Råket, Hans Kristian, et al. "Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting." Pulmonary Therapy 11, no. 2 (2025): 235. https://doi.org/10.1007/s41030-025-00287-1.

MLA (9th ed.) Citation

Råket, Hans Kristian, et al. "Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting." Pulmonary Therapy, vol. 11, no. 2, 2025, p. 235, https://doi.org/10.1007/s41030-025-00287-1.